Bangladesh's Beximco to sell generic version of Merck COVID-19 pill_老虎社区_美港股上老虎

Bangladesh's Beximco to sell generic version of Merck COVID-19 pill

Reuters2021-11-09

Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday. The...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

YYKTAN
·2021-11-09
Latest
回复
1
举报
26629536
·2021-11-09
Ok
回复
5
举报
收起
- 26629536:
  [Doubt]
  2021-11-09
  回复
  举报
- 26629536:
  [Strong]
  2021-11-09
  回复
  举报
- 26629536:
  [OK]
  2021-11-09
  回复
  举报
查看更多 2 条评论
XWB
·2021-11-09
Ok
回复
3
举报
userTesting
·2021-11-09
Ok
回复
4
举报
收起
- jc0110:
  ok
  2021-11-09
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-09 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137172640","market":"us","top_or_hot":-1,"title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill","media":"Reuters","content":"<div>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 16:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","article_id":"1137172640","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","pubTimestamp":1636447803,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"孟加拉Beximco将出售仿制版默沙东新冠肺炎药丸","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":844421187,"gmtCreate":1636453082167,"gmtModify":1636453197612,"author":{"id":"3586858995147972","authorId":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3586858995147972","idStr":"3586858995147972"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844421187","repostId":1137172640,"repostType":4,"repost":{"id":"1137172640","kind":"news","pubTimestamp":1636447803,"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","pubTime":"2021-11-09 16:50","market":"us","language":"en","title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","media":"Reuters","summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","content":"<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 16:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137172640","content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":844497531,"gmtCreate":1636449792898,"gmtModify":1636450017028,"author":{"id":"3586053412837856","authorId":"3586053412837856","name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586053412837856","idStr":"3586053412837856"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":14,"repostSize":0,"link":"https://laohu8.com/post/844497531","repostId":1137172640,"repostType":4,"repost":{"id":"1137172640","kind":"news","pubTimestamp":1636447803,"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","pubTime":"2021-11-09 16:50","market":"us","language":"en","title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","media":"Reuters","summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","content":"<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 16:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137172640","content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6510754,"gmtCreate":1636450016979,"gmtModify":1636450017008,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Doubt]","text":"[Doubt]","html":"[Doubt]"},{"id":6510751,"gmtCreate":1636450008270,"gmtModify":1636450008358,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Strong]","text":"[Strong]","html":"[Strong]"},{"id":6510748,"gmtCreate":1636449999473,"gmtModify":1636449999563,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[OK]","text":"[OK]","html":"[OK]"},{"id":6510745,"gmtCreate":1636449989907,"gmtModify":1636449989936,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Applaud]","text":"[Applaud]","html":"[Applaud]"},{"id":6510744,"gmtCreate":1636449983894,"gmtModify":1636449983923,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Bless]","text":"[Bless]","html":"[Bless]"}],"langContent":"CN"},{"id":844403976,"gmtCreate":1636448607818,"gmtModify":1636448608108,"author":{"id":"4087443275212920","authorId":"4087443275212920","name":"XWB","avatar":"https://static.tigerbbs.com/4ef27121d1015c7d31eb417553b2e797","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4087443275212920","idStr":"4087443275212920"},"htmlText":"&nbsp;Ok","listText":"&nbsp;Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844403976","repostId":1137172640,"repostType":4,"repost":{"id":"1137172640","kind":"news","pubTimestamp":1636447803,"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","pubTime":"2021-11-09 16:50","market":"us","language":"en","title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","media":"Reuters","summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","content":"<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 16:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137172640","content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":844574653,"gmtCreate":1636448174465,"gmtModify":1636448174630,"author":{"id":"4088669104286650","authorId":"4088669104286650","name":"userTesting","avatar":"https://static.tigerbbs.com/3b24fe7742aefda3019ec9856567b065","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088669104286650","idStr":"4088669104286650"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844574653","repostId":1137172640,"repostType":4,"repost":{"id":"1137172640","kind":"news","pubTimestamp":1636447803,"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","pubTime":"2021-11-09 16:50","market":"us","language":"en","title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","media":"Reuters","summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","content":"<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill<blockquote>孟加拉国Beximco将销售默克COVID-19药丸的仿制药</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 16:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p><p><blockquote>路透11月9日-孟加拉国Beximco Pharmaceuticals Ltd周二表示，在获得当地监管机构批准后，将开始销售默克公司针对COVID-19的抗病毒药物的仿制药。</blockquote></p><p> The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p><p><blockquote>这一公告标志着默克和Ridgeback Biotherapeutics的片剂molnupiravir的全球首个仿制药上市，该片剂被吹捧为抗击冠状病毒的潜在游戏规则改变者。</blockquote></p><p> Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p><p><blockquote>Molnupiravir上周在英国获得了全球首个监管批准。它仍在美国和欧洲接受审查。</blockquote></p><p> Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p><p><blockquote>Beximco在一份声明中表示，该公司很快将开始在孟加拉国销售仿制药molnupiravir，这是默克品牌药丸的廉价版本，因为该公司已获得该国药品监督管理局的紧急使用授权。它补充说，出口将取决于全球监管机构的批准。</blockquote></p><p> Merck did not immediately respond to a request for comment.</p><p><blockquote>默克没有立即回应置评请求。</blockquote></p><p> The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p><p><blockquote>这家美国制药商已与至少八家印度制药商签订了molnupiravir的许可协议，旨在将这个南亚国家转变为向中低收入国家供货的制造中心。</blockquote></p><p> These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p><p><blockquote>其中包括雷迪博士实验室、Cipla、Sun Pharma、Torrent Pharmaceuticals、Emcure Pharmaceuticals和Hetero等。</blockquote></p><p> Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p><p><blockquote>Beximco表示，鉴于印度邻国孟加拉国目前的COVID-19感染率较低，预计仿制药molnupiravir的销售不会显着增加收入。</blockquote></p><p> Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p><p><blockquote>截至格林威治标准时间0825，其在伦敦上市的股价上涨6.2%，至107.25便士。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137172640","content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6510523,"gmtCreate":1636448543073,"gmtModify":1636448543183,"authorId":3576885233950935,"author":{"id":3576885233950935,"idStr":"3576885233950935","authorId":3576885233950935,"name":"jc0110","avatar":"https://static.tigerbbs.com/e09e5e2e4ea456938e5df81fb0919107","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844574653,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":38,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}